Metabolomic and Lipidomic Analysis of Manganese-Associated Parkinsonism: a Case-Control Study in Brescia, Italy

Freeman Lewis1, Daniel Shoieb2, Somaiyeh Azmoun1

  • 1Environmental Health Sciences, Florida International University, 11200 SW 8th St, Miami, 33199, Florida, USA.

Abstract

Insights

Excessive manganese exposure and Parkinson's disease (PD) create distinct metabolic and lipid profiles. These changes may serve as biomarkers for manganese-induced Parkinsonism (MnIP).

Area of Science:

  • Neuroscience
  • Metabolomics
  • Lipidomics

Background:

  • Excessive manganese (Mn) exposure causes neurotoxicity, leading to Mn-induced Parkinsonism (MnIP) with cognitive and motor deficits.
  • Limited metabolomic and lipidomic research exists for Parkinsonism (PD) patients, especially concerning Mn exposure.

Purpose of the Study:

  • To investigate distinct metabolomic and lipidomic profiles in individuals based on manganese exposure status and Parkinson's disease diagnosis.
  • To explore the interaction effects of manganese exposure and Parkinson's disease on metabolic and lipidomic profiles.

Main Methods:

  • A case-control study with a 2x2 factorial design involving 97 participants.
  • Four groups: non-exposed controls, exposed controls, non-exposed PD, and exposed PD.
  • Untargeted metabolomic and lipidomic analyses of whole blood samples using UHPLC-MS, followed by statistical analysis (PCA, PLS-DA, ANCOVA).

Main Results:

  • Metabolomic analysis showed significant alterations in alanine, aspartate, glutamate, and butanoate metabolism, as well as vitamin B6 metabolism.
  • Differential abundances of 3-sulfoxy-L-Tyrosine, glycocholic acid, and palmitelaidic acid were linked to disease, exposure, and interaction effects.
  • Lipidomic analysis revealed significant alterations in ferroptosis and sphingolipid signaling pathways, with differential abundances in triacylglycerols, ceramides, and phosphatidylethanolamines.

Conclusions:

  • Parkinson's disease and manganese exposure induce unique metabolomic and lipidomic changes.
  • These distinct profiles show potential as biomarkers for Mn-induced Parkinsonism (MnIP).
  • Further research is warranted to validate these findings and explore their clinical utility.

Related Concept Videos

Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...